Genomic and molecular profiling predicts response to temozolomide in melanoma

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 502-510

  Augustine, Christina K ^a,b,c   Yoo, Jin Soo ^a   Potti, Anil ^a,b   Yoshimoto, Yasunori ^a,c   Zipfel, Patricia A ^a,c   Friedman, Henry S ^a   Nevins, Joseph R ^a,b   Ali Osman, Francis ^a   Tyler, Douglas S ^a,c  

^a Department of Surgery ^*  (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG RESISTANCE; DRUG SENSITIVITY; EXCISION REPAIR; GENE ACTIVITY; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN CELL; IC 50; MELANOMA; MELANOMA CELL; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CELL LINE, TUMOR; DACARBAZINE; DNA METHYLATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MICROSATELLITE REPEATS; NEOPLASM METASTASIS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 59449085721     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1916     Document Type: Article

References (49)

1. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.
2. Horspool KR, Stevens MF, Newton CG, et al. Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents. J Med Chem 1990; 33:1393-9.
3. Middleton MR, Grab JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-66.
4. Spiro T, Liu L, Gerson S. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Forum (Genova) 2000;10:274-85.
5. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
6. Gupta V, Jani JP, Jacobs S, et al. Activity of melphalan in combination with the glutathione transferase inhibitor sulfasalazine. Cancer Chemother Pharmacol 1995;36:13-9.
7. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55: 2853-7.
8. Grubbs EG, Ueno T, Abdel-Wahab O, et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery 2004;136: 210-8.
9. 6-benzylguanine. Mol Cancer Ther 2006; 5:732-8.
10. Friedman HS, KerbyT, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6:2585-97.
11. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003;361:1590-6.
12. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
13. Pavey S, Johansson P, Packer L, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
14. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005;102:6092-7.
15. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
16. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
17. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300.
18. 6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N-nitro-N-nitrosoguanidine. Carcinogenesis 1984;5:1641 -7.
19. 6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res 1991;19:6163-7.
20. Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther 2007;6:1492-500.
21. Ross Ml. Early-stage melanoma: staging criteria and prognostic modeling. Clin Cancer Res 2006;12: 2312-9s.
22. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40: 1825-36.
23. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-64.
24. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12: 1114-23.
25. Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer 2007;109:306-12.
26. Paul MJ, Summers Y, Calvert AH, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002;12:175-8.
27. Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg 2004;188:532-7.
28. Buzaid AC. Management of metastatic cutaneous melanoma. Oncology (Williston Park) 2004;18: 1443-50; discussion 57-9.
29. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007;56:275-87.
30. 6-alkylguanine-DNA alkyl- transferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-29.
31. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400.
32. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997;57:2933-6.
33. 6-alkylguanine-DNA alkyl-transferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16: 3851 -7.
34. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
35. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004;10: 4933-8.
36. 6- Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78: 1199-202.
37. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000;88:469-73.
38. 6-methylguanine-DNA methyl-transferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Melanoma Res 2002;12:335-42.
39. Rietschel P, Wolchok JD, Krown S, et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008;26: 2299-304.
40. Ranson M, Hersey P, Thompson D, et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007;25:2540-5.
41. 41. Tentori L, Portarena I, Barbarino M, et al. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly(ADP-ribose) polymerase inhibitor. Mol Pharmacol 2003;63:192-202.
42. 6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chlor- oethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003;304:661-8.
43. Drablos F, Feyzi E, Aas PA, et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 2004;3:1389 -407.
44. 6-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
45. 6- methylguanine-DNA methyltransferase expression. Pharmacol Ther 1997;74:285-97.
46. 6- methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
47. 6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008;50: 549-53.
48. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92: 1855-61.
49. Augustine CK, Yoshimoto Y, Gupta M, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008; 68:3777-84.